Novo Nordisk A/S (NYSE:NVO) Stake Raised by Bremer Bank National Association

Bremer Bank National Association grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 1.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 49,479 shares of the company’s stock after buying an additional 924 shares during the period. Bremer Bank National Association’s holdings in Novo Nordisk A/S were worth $4,256,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in the stock. Strategic Investment Solutions Inc. IL acquired a new position in shares of Novo Nordisk A/S during the second quarter valued at approximately $25,000. Daiwa Securities Group Inc. acquired a new position in shares of Novo Nordisk A/S during the third quarter valued at approximately $28,000. Capital Performance Advisors LLP acquired a new position in shares of Novo Nordisk A/S during the third quarter valued at approximately $42,000. Carolina Wealth Advisors LLC acquired a new position in shares of Novo Nordisk A/S during the third quarter valued at approximately $48,000. Finally, M&R Capital Management Inc. increased its stake in shares of Novo Nordisk A/S by 260.5% during the third quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock valued at $49,000 after acquiring an additional 297 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 5.2 %

NYSE NVO opened at $78.74 on Monday. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock has a market cap of $353.33 billion, a price-to-earnings ratio of 25.48, a PEG ratio of 0.92 and a beta of 0.45. The firm’s 50 day moving average price is $97.76 and its two-hundred day moving average price is $117.05.

Analysts Set New Price Targets

A number of research firms recently commented on NVO. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Finally, BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $140.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.